A carregar...
Clinical and economic impact of ibalizumab for people with multidrug-resistant HIV in the United States
BACKGROUND: We projected the clinical outcomes, cost-effectiveness, and budget impact of ibalizumab plus an optimized background regimen (OBR) for people with multidrug-resistant HIV in the US. METHODS: Using the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) microsimulation model and a...
Na minha lista:
| Publicado no: | J Acquir Immune Defic Syndr |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7066538/ https://ncbi.nlm.nih.gov/pubmed/31929403 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0000000000002241 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|